Long-Term Renal Function with Cardiac Contractility Modulation Therapy
Authors:
- Goekhan YuecelGYGoekhan Yuecel
- Babak YazdaniBYBabak Yazdani
- Kristin SchreinerKSKristin Schreiner
- Christian FastnerCFChristian Fastner
- Svetlana HetjensSHSvetlana Hetjens
- Faeq Husain-SyedFHFaeq Husain-Syed
- Mathieu KruskaMKMathieu Kruska
- Daniel DuerschmiedDDDaniel Duerschmied
- Bernhard K. KrämerBKBernhard K. Krämer
- William T. AbrahamWAWilliam T. Abraham
- Ibrahim AkinIAIbrahim Akin
- Juergen KuschykJKJuergen Kuschyk
Open Access
- 21 June 2024
- journal article
- research article
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 14 (1) , 1
Abstract
Background: Cardiac implantable electrical devices are able to affect kidney function through hemodynamic improvements. The Cardiac Contractility Modulation (CCM) is a device-based therapy option for patients with symptomatic chronic heart failure (HF) despite optimized medical treatment. The long-term cardiorenal interactions for CCM treated patients are yet to be described. Methods: CCM recipients (n=187) from the Mannheim Cardiac Contractility Modulation Observational Study (MAINTAINED) were evaluated in the long-term (up to 60 months) for changes in serum creatinine, estimated glomerular filtration rate (eGFR), other surrogate markers of kidney function, and the chronic kidney disease (CKD) stage-distribution. With regard to kidney function at baseline, the patients were furthermore grouped to either advanced CKD (aCKD, CKD-stage ≥3, eGFR≤59mL/min/1.73 m2, n=107) or preserved kidney function and mild CKD (pCKD, CKD stages 1-2, eGFR≥60mL/min/1.73 m2, n=80). The groups were compared for differences regarding kidney function, New York Heart Association classification (NYHA), biventricular systolic function, HF hospitalizations and other parameters in the long-term (60 months). Results: CKD stage distribution remained stable during the entire follow-up (p=0.65). An increase in serum creatinine (1.47±1 vs. 1.6±1mg/dL) with a corresponding decline of eGFR (58.2±23.4 vs. 54.2±24.4mL/min/1.73 m2, both p<.05) were seen after 60 months but not before for the total cohort, which was only significant in pCKD patients in terms of group comparison. Mean survival (54.3±1.3 vs. 55.3±1.2months, p=0.53) was comparable in both groups. Improvements in NYHA (3.11±0.46 vs. 2.94±0.41 to 2.28±0.8 vs. 1.94±0.6) and LVEF (24.8±7.1 vs. 22.9±6.6 to 31.1±11.4 vs. 35.5±11.1%) were likewise similar after 60 months (both p <.05). The aCKD patients suffered from more HF-hospitalizations and ventricular tachycardias during the entire follow-up period (both p<.05). Conclusions: The kidney function parameters and CKD stage distribution might remain stable in CCM treated HF patients in the long-term, who experience improvements in LVEF and functional status, regardless of their kidney function before. An impaired kidney function might be associated with further cardiovascular comorbidities and more advanced HF before CCM, and could be an additional risk factor of HF complications afterwards.Keywords
This publication has 40 references indexed in Scilit:
- The prevalence and influencing factors of frailty in patients with chronic kidney disease: a systematic review and meta-analysisInternational Urology and Nephrology, 2023
- Cardiac Resynchronization Therapy and Cardiac Contractility Modulation in Patients with Advanced Heart FailureHeart Failure Clinics, 2021
- Optimized Implementation of Cardiac Resynchronization Therapy: A Call for Action for Referral and Optimization of CareEuropean Journal of Heart Failure, 2020
- Response to Cardiac Resynchronization Therapy Across Chronic Kidney Disease StagesJournal of Cardiac Failure, 2019
- Medication Dosing for Heart Failure with Reduced Ejection Fraction — Opportunities and ChallengesEuropean Journal of Heart Failure, 2018
- Impact of Renal Function on Survival After Cardiac Resynchronization TherapyThe American Journal of Cardiology, 2017
- Cardiac contractility modulation: a novel approach for the treatment of heart failureHeart Failure Reviews, 2016
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Cardiac Resynchronization Therapy Improves Renal Function in Human Heart Failure With Reduced Glomerular Filtration RateJournal of Cardiac Failure, 2008
- Cardiac Contractility Modulation by Non-Excitatory Currents: Studies in Isolated Cardiac MuscleEuropean Journal of Heart Failure, 2005